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Production of a Transgenic Mosquito Expressing 
Circumsporozoite Protein,  a Malarial Protein,  in the Salivary 
Gland of Anopheles stephensi (Diptera: Culicidae)
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Division of Medical Zoology,  Jichi Medical University,  Shimotsuke,  Tochigi 329-0498,  Japan
We are producing a transgenic mosquito,  a ﬂying syringe,  to deliver a vaccine protein to human 
beings via the saliva the mosquito deposits in the skin while biting.  The mosquito produces a vaccine 
protein in the salivary gland (SG) and deposits the protein into the hostʼs skin when it takes the hostʼs 
blood.  We chose circumsporozoite protein (CSP),  currently the most promising malaria vaccine candi-
date,  to be expressed in the SG of Anopheles stephensi.  To transform the mosquitoes,  plasmid con-
taining the CSP gene under the promoter of female SG-speciﬁc gene,  as well as the green ﬂuorescent 
protein (GFP) gene under the promoter of 3xP3 as a selection marker in the eyes,  was injected into 
more than 400 eggs.  As a result,  ﬁve strains of GFP-expressing mosquitoes were established,  and suc-
cessful CSP expression in the SG was conﬁrmed in one strain.  The estimated amount of CSP in the SG 
of the strain was 40ng per mosquito.  We allowed the CSP-expressing mosquitoes to feed on mice to 
induce the production of anti-CSP antibody.  However,  the mice did not develop anti-CSP antibody even 
after transgenic mosquitoes had bitten them several times.  We consider that CSP in the SG was not 
secreted properly into the saliva.  Further techniques and trials are required in order to realize vac-
cine-delivering mosquitoes.
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osquitoes are nuisance to human beings because 
they puncture the skin to obtain blood,  which 
they use for their eggs.  They deposit saliva in the skin 
when they take blood,  and this causes itching [1].  
They also transmit pathogens of diseases such as 
malaria,  ﬁlarisis,  yellow fever,  and dengue fever.  
People have long tried to prevent mosquitoes from 
biting using mosquito nets [2] and repellents [3].  
Moreover,  people have attacked mosquitoes with 
insecticides to eliminate them [4,  5].  These struggles 
have continued not only in developing countries but 
also in advanced countries.
　 In the last 30 years,  developments in genetic engi-
neering have allowed us to add new genes to wild-type 
cells or to remove protein genes from them [6].  
These technologies were used at ﬁrst in bacteria or 
yeast to obtain recombinant proteins for experiments 
and to understand the mechanisms of protein mole-
cules.  More recently,  many transgenic experiments 
have been applied to plants and animals,  including 
vertebrates and insects.  Recombinant-DNA-modiﬁed 
soybean,  cotton,  and corn are widely adopted and 
harvested around the world [7].  Transgenic mice,  
sheep,  dogs,  zebra ﬁsh,  ﬂies,  silkworms,  and so on 
have appeared in laboratories as well [8-12].  The 
objectives of genetic engineering in animals are 
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several: to understand cell diﬀerentiation,  to ﬁnd 
molecules responsible for causing speciﬁc diseases,  
and to speed up the production of meat,  ﬁsh,  and silk.
　 Some attempts have been made to create transgenic 
mosquitoes to make them non-vectors of germs or to 
reduce the germsʼ transmission ability [13,  14].  
Anopheline mosquitoes are the primary targets for 
transgenes,  because they transmit malaria parasites.  
Some laboratories,  including ours,  have succeeded in 
producing transgenic mosquitoes with lower levels of 
malaria parasites in the digestive tract after blood 
meals on malaria-infected animals [15,  16].  The goal 
of those attempts is to control disease transmission 
through genetic modiﬁcation of the mosquitoes [17].
　 We here present a new attempt to produce a useful 
protein in the mosquito salivary gland (SG) by adding 
a new gene to a mosquito chromosome.  When mosqui-
toes attach to the skin surface,  they try to ﬁnd blood 
vessels from which they can take blood.  At that time,  
they ﬁrst deposit their saliva in the skin [1].  
Mosquito saliva contains many molecules,  such as 
vasodilators,  platelet inhibitors,  an anesthetic sub-
stance,  and so on [18].  These substances dilate the 
blood vessel,  allowing the mosquito to insert its pro-
boscis into the vessel.  A mosquito can have a blood 
meal without the blood coagulating and without being 
noticed.  On the other hand,  humans develop anti-
saliva protein antibodies after experiencing several 
mosquito bites [19,  20].  Our idea is to put a gene 
encoding a useful protein into a mosquito chromosome,  
causing it to make the useful protein in its saliva and 
to inject the protein,  via the saliva,  into animals or 
human beings upon blood feeding.  We expect that the 
host would develop antibodies to the recombinant 
protein as a reaction.  If these transgenic (TG) mos-
quitoes,  whose saliva contains a vaccine protein 
against a disease,  were spread in an area where peo-
ple are suﬀering from the disease,  people who are 
daily bitten by them would develop antibodies to the 
vaccine protein,  ultimately vaccinating the community 
from the disease.  In this situation,  mosquitoes would 
play the role of vaccine deliverers [21].
　 In ﬁeld conditions of malaria-endemic areas,  for 
instance,  nearly 100 mosquitoes bite an individual per 
night,  but more than 50ｵ of the mosquitoes are nul-
liparous females (non-oviposit females) [22].  Even in 
malaria-holoendemic areas,  the percentage of mosqui-
toes infected with malaria parasites in the SG is less 
than 4ｵ among collected Anopheline mosquitoes 
[23].  Indeed,  it is important to reduce malaria-
infective mosquitoes,  but people in malaria-endemic 
areas are bitten by thousands of non-infective mosqui-
toes each year.  These non-infective mosquitoes could 
work as vaccine distributors.
　 We discovered one molecule of a platelet inhibitor 
in the SG of a model mosquito,  Anopheles stephensi,  
cloned the gene,  and named it the Anopheline anti-
platelet protein (AAPP) [24].  This molecule is 
expressed only in the female SG.  We used the upper 
stream area of the AAPP gene (aapp) as a promoter 
for the vaccine protein.  For the vaccine protein,  we 
chose circumsporozoite protein (CSP) of the malaria 
parasite.  This molecule has been studied as a malaria 
vaccine candidate [25,  26].  In a rodent malaria 
model,  a monoclonal antibody to CSP neutralizes the 
infectivity of sporozoite,  an infective form of malaria 
parasite from the mosquito [27],  and a synthetic 
peptide induces suﬃcient antibodies to protect immu-
nized mice from sporozoite challenge [28].  CSP is 
now thought to be a promising vaccine candidate mol-
ecule [29],  and recombinant proteins composed of 
CSP are being evaluated in malaria-endemic areas 
[30].  Thus,  we decided to produce a TG mosquito 
containing the promoter area of aapp followed by the 
CSP gene (csp).  We expected that the TG mosquitoes 
would express CSP in the SG and inject the recombi-
nant CSP (rCSP) into the skin of mice when the TG 
mosquitoes fed on them.
Materials and Methods
　 Mosquitoes, mice, and parasites. Anopheles 
stephensi SDA 500 strain was reared in our laboratory 
under conditions of 26℃ room temperature,  50-70ｵ 
relative humidity,  and light control of 14 h bright and 
10 hours dark.  Female BALB/c mice were purchased 
from SLC (Shizuoka,  Japan).  A rodent malaria para-
site,  Plasmodium berghei ANKA strain,  was main-
tained by cyclical passage through BALB/c mice and 
An. stephensi mosquitoes.
　 Recombinant CSP of P. berghei (rPbCSP).
The rPbCSP was expressed as His-tagged at the 
C-terminal by the baculovirus expression system,  and 
puriﬁed with a nickel column (Qiagen,  Hilden,  
Germany) as described elsewhere [31].  The rPbCSP 
is expressed with two molecular weight sizes,  70 and 
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82kDa [31].  When mice are immunized with 
rPbCSP three times,  they become protected against 
parasite challenge (unpublished data).  The protein 
concentration of rPbCSP was measured using a Bio-
Rad Protein Assay Kit (Bio-Rad Laboratories,  
Hercules,  CA,  USA).  Bovine serum immunoglobulin 
was used as a standard for the protein concentration.
　 Preparation of anti-CSP antibody. For 
anti-CSP antibody production,  0.5ml of rPbCSP 
solution (50µg/ml) and 0.5ml of alum,  Al(OH)3 
(16mg/ml),  were well mixed and 0.2ml was injected 
intraperitoneally into each of four BALB/c mice.  
Injection was done 3 times at intervals of 2 weeks.  
Anti-CSP antibody was monitored by ELISA,  as 
shown below,  and the mice were sacriﬁced to take 
their sera.  The sera were used as the anti-CSP anti-
body.
　 Preparation of anti-saliva antibody. To 
prepare anti-saliva antibody,  4 female BALB/c mice 
were each bitten by 100 female mosquitoes every 2 
weeks for a 10-week period (5 biting sessions).  
Development of an anti-saliva antibody in the mice was 
conﬁrmed by ELISA as shown below,  and sera were 
taken from the mice.  The sera were used as the anti-
saliva antibody.
　 Evaluation for antibody titer by ELISA.
For the evaluation of anti-CSP antibody,  8 wells of a 
96-well assay plate were coated with 100µl of 
rPbCSP (1µg/ml) in 0.05M carbonate buﬀer (pH9.6),  
and 8 wells were ﬁlled with 100µl of carbonate buﬀer 
without antigen.  The plate was incubated at 4℃ 
overnight.
　 For the evaluation of anti-saliva antibody,  10 pairs 
of SG were collected from female mosquitoes,  
destroyed in 1.0ml of carbonate buﬀer by sonication 
(1 sec×5 times),  and centrifuged (8,000rpm for 
3min).  The supernatant was used as the SG antigen.  
Eight wells were each coated with 100µl of SG anti-
gen.
　 Two microliters of blood was collected from the tail 
of each mouse 7 days after the injection of rPbCSP or 
mosquito biting.  The blood was mixed with 0.8ml of 
phosphate-buﬀered saline containing 1ｵ bovine serum 
albumin (BSA/PBS) and centrifuged at 8,000rpm for 
3min.  The supernatant was used as an 800-fold-
diluted serum.
　 After the antigen solution was removed and washed 
twice,  the wells of an ELISA plate were blocked with 
150µl of 1ｵ BSA/PBS for 30min.  After removing 
the blocking solution,  100µl of the mouse serum 
diluted 800-fold was distributed into each of 2 antigen 
wells and 2 no-antigen wells and incubated for 2h.  As 
the second antibody,  rabbit anti-mouse IgG conjugated 
with horseradish peroxidase (HRP) (Bio-Rad 
Laboratories) diluted 3,000-fold was distributed into 
each of the same wells and incubated for 1h.  After 
the plate was washed,  the substrate solution,  a mix-
ture of 0.04ｵ 2,2ʼ-azino-bis(3-ethylbenzthiazoline-6-
sulfonic acid) (ABTS) (Sigma-Aldrich,  St.  Louis,  
MO,  USA),  0.05ｵ H2O2 in 0.05M phosphate,  and 
0.1M citrate buﬀer (pH4.5) was added.  After 
20-60min,  a green color appeared.  The absorption 
was measured at a wavelength of 405 nm by a 
microplate reader,  Spectra Max M5 (Molecular 
Devices,  Tokyo,  Japan).  The mean absorbance of 
antigen wells minus the mean absorbance of no-antigen 
wells was taken as the OD value for the antigen.
　 Plasmid construction (Fig. 1). The anoph-
eline anti-platelet protein gene (aapp) promoter region 
and its signal peptide coding region of An. stephensi 
[24] (1,746bp) were ampliﬁed with a primer pair of 
AAPP-F-AscI (5ʼ-GGCGCGCCTTATAAGACGGAG 
CTCATTGTCGCTCGTC-3ʼ) and AAPP-R-SmaI (5ʼ- 
CCCGGGCGGCCGTGCGGATACGATCAGCGC 
AAGGC-3ʼ),  then cloned into the pCR-BluntII TOPO 
vector (Invitrogen,  Carlsbad,  CA,  USA) (plasmid a).  
The open reading frame of the P. berghei CSP gene 
without a signal peptide coding region or a C-terminal 
GPI-anchor domain coding region was ampliﬁed with a 
primer pair of PbCS-F-SmaI (5ʼ-CCCGGGCAAAAT 
AAAATCATCCAAGCCCAAAGGAAC-3ʼ) and 
PbCS-R-SpeI (5ʼ-ACTAGTTATTTATCCATTTTAC 
AAATTTCAGTATCAATATC-3ʼ),  then cloned into 
the vector (plasmid b).  The 3ʼ non-coding region of the 
AAPP gene was ampliﬁed with a primer pair of 
3UTR-F-SpeI (5ʼ-ACTAGTGAAACACACCGTTAA 
CGACAC-3ʼ) and 3UTR-R-XbaI (5ʼ-TCTAGATATTC 
AAAGGTCCACAAATGTC-3ʼ),  then cloned into the 
vector (plasmid c).  The inserts of plasmids a,  b,  and 
c were serially cloned into the pENTR4 vector 
(Invitrogen) (donor vector).
　 The pBac [3xP3-EGFP] vector [11] and helper 
plasmid were kindly provided by Professor A. S. 
Raikhel (Department of Entomology,  University of 
California at Riverside,  USA).  The pBac [3xP3-
EGFP] vector was digested with AscI,  blunted with a 
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Klenow fragment,  and dephosphorylated.  The reading 
frame cassette A (Invitrogen) was then cloned into the 
vector (destination vector).  The insert in the donor 
vector was cloned into the destination vector by 
Gateway LR clonase reaction (Invitrogen).  The 
resulting plasmid (pBac-AAPP-PbCSP: Fig.  1A) 
was expected to drive CSP gene expression under the 
AAPP promoter.  The pBac-AAPP-PbCSP plasmid 
was mixed with piggyBac helper (Fig.  1B) and micro-
injected into the eggs of A. stephensi as described 
below.
　 Microinjection of the plasmids into mosquito 
eggs. The mosquito microinjection was performed 
as described elsewhere [32].  In brief,  blood-fed An. 
stephensi mosquitoes were allowed to lay eggs on a wet 
ﬁlter sheet 72-84h after a blood meal.  Eggs were laid 
and injected with plasmids within 90min after oviposi-
tion.  Injection was done by glass needles (Eppendorf,  
Hamburg,  Germany) with a mixture of the pBac-
AAPP-PbCSP (500ng/µl) and piggyBac helper 
(300ng/µl) in injection buﬀer (5mM KCl,  0.1mM 
Na2HPO4,  pH6.8).  After injection,  the eggs were 
placed in water and observed for hatching.  Hatched 
larvae were analyzed on a ﬂuorescence microscope at 
a wavelength of 490nm to detect GFP expression.
　 Selection of transgenic mosquito. We 
selected GFP-expressing larvae and made them 
emerge (G0).  One G0 adult female (or male) express-
ing GFP was put in a cage containing 5 wild-type 
males (or females).  After mating and blood feeding,  
each female was allowed to lay eggs individually.  
Hatched larvae were observed under a ﬂuorescence 
microscope,  and GFP-expressing larvae were isolated 
as a G1 strain.  Among the same batch of G1,  mosqui-
toes were allowed to mate,  feed,  and lay eggs.  
Hatched larvae were observed and GFP-expressing 
larvae were isolated as the G2 of the strain.
　 Selection of CSP-expressing strain. Ten 
pairs of SG were collected from G2 female adults in 
each strain,  destroyed in 1.0ml of carbonate buﬀer by 
sonication (1 sec×5 times),  and centrifuged (8,000rpm 
for 3min).  The supernatant was used as the SG anti-
gen.  Then,  100µl of SG antigen was distributed into 
each of four wells of an ELISA plate and allowed to 
stand at 4℃ overnight.  After blocking with 1ｵ 
BSA/PBS,  anti-CSP antibody diluted 800-fold was 
poured into 2 wells,  and normal mouse serum diluted 
800-fold was poured into 2 other wells.  Incubation 
with the secondary antibody and the subsequent proce-
dures were the same as described above.
　Western blotting. Ten pairs of salivary glands 
were collected from both TG female mosquitoes and 
wild-type female mosquitoes.  Samples were separated 
on a 10ｵ SDS-polyacrylamide gel under reducing 
conditions (with 2ｵ 2-mercaptoethanol),  transferred 
onto a nitrocellulose (NC) sheet,  and probed with 
mouse anti-CSP antibody diluted 800-fold.  The NC 
sheet was next incubated with anti-mouse IgG conju-
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Fig. 1　 Construction of plasmids injected into mosquito eggs.  A,  Two DNA fragments (a and c) were ampliﬁed from A. stephensi DNA.  
One DNA fragment (b) was ampliﬁed from P. berghei DNA.  Three fragments were inserted in tandem in a plasmid vector downstream from 
the GFP gene.  A promoter,  3xP3,  was adopted to induce GFP expression in the eyes of mosquitoes as a selection marker.  
AAPP: anopheline anti-platelet protein.  ss: signal sequence. CSP: circumsporozoite protein; B,  To improve uptake of the recombinant 
plasmid in the mosquito chromosome,  a piggyback helper plasmid was added when microinjection was performed.  Hsp: heat-shock pro-
tein.
gated with HRP (Bio-Rad Laboratories) diluted 3,000 
fold,  then reacted with substrate,  SuperSignal West 
Pico Chemiluminescent Substrate (Thermo Fisher 
Scientiﬁc,  Rockford,  IL,  USA).  Positive bands were 
visualized in a Lumino Image Analyzer (LAS-1000) 
(Fuji Film,  Tokyo,  Japan).
　 Immunization of mice via biting by CSP-
expressing transgenic mosquitoes. Two female 
BALB/c mice were bitten by each of 50 TG female 
mosquitoes every 2 weeks over a 10-week period (5 
biting sessions).  Two other mice were bitten by wild-
type female mosquitoes under the same protocol.  Two 
microliters of mouse blood was collected from the tail 
vein 7 days after the ﬁnal mosquito biting.  Antibody 
assay to CSP and SG was carried out by ELISA as 
described above.
　 Comparison of CSP contents in the SG before 
and after blood feeding. A pair of SG of the 
TG female mosquitoes before blood feeding was trans-
ferred in 0.5ml of carbonate buﬀer,  destroyed,  and 
centrifuged as above.  Another TG female mosquito 
was dissected within 10min after full blood feeding,  
and a pair of SG were isolated and treated as 
described above.  Each antigen solution was added to 
4 wells,  100µl per well.  Anti-CSP antibody (800-
fold) was reacted with the 2 wells and anti-saliva 
antibody (800-fold) was reacted with the other 2 wells.  
Incubation with the secondary antibody and the subse-
quent procedures were the same as described above.  
Eight SG samples in each group were tested.
Results and Discussion
　 Isolation of TG mosquito. We injected recom-
binant plasmid into 461 mosquito eggs,  from which 
109 larvae hatched and 103 adults emerged (G0 
adults: 56 males and 47 females).  We crossed these 
G0 males with wild-type females and allowed them to 
lay eggs.  We also crossed G0 females with wild-type 
males and allowed them to lay eggs.  GFP-expressing 
larvae were selected and allowed to emerge.  From the 
G0 male group we established 1 strain,  and from the 
G0 female group we established 4 strains.  The rate of 
establishment for 5 strains from the 461 egg injec-
tions (1.1ｵ) was reasonable compared with our previ-
ous experiments [16,  33] and with the results 
obtained by other groups [15,  32].
　 As shown in Fig.  2,  larvae and adult TG mosqui-
toes expressed GFP in the eyes as expected,  because 
the 3xP3 promoter works speciﬁcally in the eyes 
[11].  Unexpectedly,  GFP was expressed not only in 
the eyes but also in the SG (Fig.  2C).  3xP3 marker 
protein is typically used for Drosophila (a small ﬂy) 
transgenesis,  and expression of a transgene in the SG 
of Drosophila has not been conﬁrmed.  Thus,  this is the 
ﬁrst observation that the 3xP3 promoter works in the 
SG of a mosquito.  The SG cells may contain some 
transcriptional factors to attach to the 3xP3 promoter.  
GFP expression in female SG was observed among all 
strains of CS1 to CS5.  In the SG,  the highest 
expression of GFP was observed in the distal region 
of the lateral lobes in all SGs (Fig.  2C).  In contrast,  
GFP was not always expressed in the median lobes.  
This tendency was similar to the results of a previous 
report [33].
　 Recombinant CSP expression in the SG. We 
expected that rCSP would be expressed in the SG of 
TG mosquitoes.  ELISA was performed to conﬁrm 
rCSP expression.  Ten pairs of SG from each strain 
of TG female mosquitoes were collected and used as 
ELISA antigens.  Only one of the 5 strains (CS2) 
showed strong reactivity against anti-CSP antibody 
(Fig.  3).  This means that the 3x3P promoter worked 
in all 5 strains,  but that the aapp promoter worked 
only in strain CS2.  The exact reason for this is 
unknown,  but may be related to the insertion site in 
the mosquito chromosome.  The insertion site may 
allow the 3xP3 promoter,  but not the aapp promoter,  
to work.  A possible explanation for this is that some 
of the transcriptional factors that attach to the aapp 
promoter to start AAPP expression react mostly with 
the intrinsic aapp promoter.  The inserted aapp pro-
moter cannot react with these factors,  and thus rCSP 
may be expressed in only small amounts.
　Western blotting analysis and estimation of 
rCSP expression. Western blotting was per-
formed with 10 pairs of SG dissected from transgenic 
mosquitoes of the CS2 strain.  A band of 38kDa 
reacted with anti-CSP in the TG mosquito lane (Fig.  
4).  The molecular size was as we expected for rCSP.  
This indicates that we succeeded in producing a for-
eign protein of rCSP in the mosquito SG.  A com-
parison of the density of the 38kDa band with those of 
the positive control bands of a series of diﬀerent 
amounts of rPbCSP revealed that the amount of 
rCSP in the CS2 lane was equivalent (in reactivity 
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with the anti-CSP antibody) to 400ng rPbCSP.  This,  
in turn,  indicated that approximately 40ng of rCSP 
was expressed in one pair of SG in the TG mosquito.
　 Besides the 38kDa band,  some other faint bands 
appeared in the CS2 lane.  The molecular sizes of 
these bands were 26,  48,  64,  and 80kDa.  Even in 
the reducing conditions (with 2ｵ 2-mercaptoethanol),  
some intermolecular re-binding may have occurred.  
There is another possibility that rCSP binds to some 
molecules of the SG components such as ubiquitins,  
proteosome-associated cofactors [34].
　 Anti-CSP antibody in mice bitten by TG mos-
quitoes. Two Female BALB/c mice were each 
bitten by 50 TG female mosquitoes of the CS2 strain 
every 2 weeks over a 10-week period.  The mice 
developed anti-SG antibody but did not develop anti-
CSP antibody (Fig.  5).  In our prediction,  20ｵ of 
rCSP (about 8ng of rCSP per mosquito) in the SG 
should be injected into a mouse during a single blood 
feeding.  In each blood feeding,  a mouse received 50 
TG mosquito bites and received a total of 400ng of 
rCSP in the skin.  As these blood feedings were con-
ducted 5 times,  each mouse was injected with 
2,000ng of rCSP.  From these injections,  the mice 





Fig. 2　 Transgenic mosquito of A. stephensi expressing GFP.  A,  Larvae expressing GFP in the eyes.  Since each larva was placed into 
its own wells of a 96-well plate,  auto-ﬂuorescence appeared from the well edge; B,  Adult female expressing GFP in the eyes; C,  
Unexpectedly,  GFP was expressed in the SG of transgenic mosquitoes.  As a reference,  the SG of a wild-type mosquito was taken at the 
phase condition.  Arrow heads (▶) show the lateral lobes of SG,  and the other arrow heads (▷) show the median lobes of SG.  No GFP 
expression was observed in the SG of wild-type mosquitoes.
should have developed anti-CSP antibody in the serum.  
However,  no antibody against rPbCSP was detected 
in the mice.  Only anti-SG antibody was detected in the 
mouse serum.  In our experience,  2 injections each of 
1,000ng rPbCSP are suﬃcient to develop anti-
rPbCSP in mice (unpublished observation).  Thus,  we 
consider the possibility that rCSP was not secreted as 
we had expected in the saliva of the TG mosquito and 
thus was not injected into the skin during blood feed-
ing.
　 Comparison of CSP contents in the SG before 
and after blood feeding. We performed ELISA 
with antigens of the SG before and after blood feed-
ing.  The amount of rCSP in the SG after blood feed-
ing did not decrease,  although the amount of total 
saliva protein did decrease (Fig.  6).  This indicates 
that the TG mosquitoes consume a lot of saliva during 
blood feeding and that the saliva does not contain 
rCSP.
　 We used the aapp promoter for rCSP expression 
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Fig. 3　 Evaluation of CSP expression in SG among 5 mosquito 
strains.  SG was taken from the 5 strains and tested as an antigen.  
Anti-CSP was used as the ﬁrst antibody.  SG from the CS2 strain 
reacted highly to anti-CSP.  NMS (normal mouse serum) was used 
as a control antibody.  The test was conducted 3 times.
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Fig. 4　 Western blotting analysis of CS2 strain salivary glands.  A 38kDa band appeared after the reaction with anti-CSP antibody.  The 
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Bitten by TG mosquitoes Bitten by WT mosquitoes
Fig. 5　 Anti-CSP antibody and anti-saliva antibody evaluated by 
ELISA.  Mice 1 and 2,  which were bitten by TG mosquitoes of the 
CS2 strain,  did not develop anti-CSP antibody.  All 4 mice devel-
oped anti-saliva antibody.  The test was conducted 3 times.
because AAPP was conﬁrmed to be secreted in the 
saliva and injected into the skin during blood feeding 
[24].  However,  we obtained the disappointing result 
that the TG mosquito did not properly release the 
foreign protein into the mouse skin.  One possible 
explanation is that rCSP may have been captured by 
some components of the SG cells,  such as ubiquitins 
[35].  As shown in Fig.  4,  rCSP was expressed as 
some larger molecules in Western blot analysis.  This 
ﬁgure suggests the possibility of “captured rCSP” in 
the SG.  According to this hypothesis,  rCSP cannot 
be secreted in the saliva because of its molecular 
characteristics,  even if it has a secretion signal.  We 
are preparing a new construct using the aapp promoter 
and aapp secretion signal with other foreign protein 
genes to test this hypothesis.
　 In summary,  we presented a transgenic mosquito 
expressing a foreign protein in the SG.  The expressed 
protein was rCSP,  a promising malaria vaccine candi-
date protein.  The amount of rCSP in one pair of SG 
was estimated to be 40ng.  If 20ｵ of rCSP in the SG 
is injected into a mouse during a single blood feeding 
band there are 50 mosquito bites on the mouse,  8×
50ng of CSP should be injected and anti-CSP anti-
body should be developed in the mouse after several 
episodes of blood feeding.  Since we did not succeed in 
preparing such a TG mosquito,  we will develop new 
constructs for producing alternative TG mosquitoes.
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